Pharma BD Deal Intelligence
Anadys CEO Steve Worland: 'With Roche's considerable capabilities and experience in HCV, we believe this acquisition provides the best chance of success for…
Roche to acquire Anadys at $3.70/share — a 256% premium — adding Phase 2b setrobuvir and TLR7 agonist ANA773 to its HCV portfolio in a clear move toward…
Roche terminated setrobuvir development in July 2015 — four years post-acquisition — after Gilead's sofosbuvir-based all-oral regimens made non-nucleoside…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Roche announced acquisition of Anadys for $3.70/share cash (~$230M), a 256% premium. Strategic HCV consolidation aimed at all-oral interferon-free regimens; competitive response to Gilead/Pharmasset and BMS/Inhibitex.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Anadys Pharmaceuticals, Inc. (this deal) | 2011 | $230M | 17 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2011 deals · Roche Holding AG deals · Infectious Disease deals